checkAd
    Startseite > Aktien > ChromaDex > Nachrichten
    ChromaDex Aktie
    2,8800
     
    EUR
    -1,37 %
    -0,0400 EUR
    Letzter Kurs 18:45:57 Tradegate
    2,8400
     
    EUR
    1.410 STK
    Geldkurs 18:50:49
    2,8800
     
    EUR
    1.380 STK
    Briefkurs 18:50:49
    ISIN: US1710774076 · WKN: A2AG5N · SYM: OCD1 · USA

    Neueste Nachrichten

    ChromaDex’s Niagen Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
    14:32 Uhr · Business Wire (engl.) · ChromaDex
    ChromaDex Corporation Reports First Quarter 2024 Financial Results
    08.05.24 · Business Wire (engl.) · ChromaDex
    ChromaDex’s NIAGEN (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar Cellular Nutrition Cellular Energy Supplement
    30.04.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe
    25.04.24 · Business Wire (engl.) · ChromaDex
    ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
    24.04.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen at Sprouts Farmers Market
    23.04.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Announces Tru Niagen is Now Third-Party Verified Through the Alkemist Assured Transparency Program
    26.03.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
    06.03.24 · Business Wire (engl.) · ChromaDex
    ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
    21.02.24 · Business Wire (engl.) · ChromaDex
    ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
    26.01.24 · Business Wire (engl.) · ChromaDex
    ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen
    20.12.23 · Business Wire (engl.) · ChromaDex
    A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
    30.11.23 · Business Wire (engl.) · ChromaDex